Botrytis Cinerea

Dosage for Botrytis Cinerea is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity and clinical history.

Diagnostic Dosing

• Scratch/Prick Test: Typically uses a 1:10 or 1:20 w/v concentration. A single drop is applied to the skin, and the skin is pricked through the drop.
• Intradermal Test: If the prick test is negative, an intradermal injection of 0.02 mL to 0.05 mL of a much more dilute solution (e.g., 1:1000 w/v) may be administered.

Therapeutic Dosing (Immunotherapy)

• Build-up Phase: Injections start at a very low dose (e.g., 0.05 mL of a 1:100,000 w/v solution) and are administered once or twice weekly. The dose is gradually increased until the 'maintenance dose' is reached.
• Maintenance Phase: Once the effective dose is reached, the interval between injections is increased to every 2 to 4 weeks. A typical maintenance dose might be 0.5 mL of a 1:100 or 1:20 w/v solution, depending on patient tolerance.

Botrytis Cinerea is used in children, but the safety and efficacy have not been established in very young children (typically under age 5), primarily because they may not be able to cooperate with the procedure or report systemic symptoms. For older children, the dosing schedule is generally similar to adults but may be adjusted based on the child's body mass and the severity of their allergic reactions. Healthcare providers exercise extreme caution in pediatric patients with comorbid asthma.

Renal Impairment

No specific dosage adjustments are provided in the manufacturer's labeling for patients with renal impairment, as the systemic load of the protein extract is minimal.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment, as the metabolism of the extract does not rely on liver enzymes.

Elderly Patients

Caution is advised in elderly patients because they may have underlying cardiovascular disease, which increases the risk of complications if epinephrine is needed to treat an accidental systemic reaction.

Botrytis Cinerea extracts are never self-administered. They must be administered by a healthcare professional in a clinic or hospital setting.

• Administration Route: Subcutaneous injection (for immunotherapy) or intradermal/epicutaneous (for testing).
• Observation Period: Patients MUST remain in the medical office for at least 30 minutes after every injection to monitor for signs of anaphylaxis.
• Site Rotation: For immunotherapy, injection sites should be rotated between the left and right upper arms.
• Storage: Extracts should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should not be frozen.

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed.

• Gap of 1-2 weeks: Usually, the same dose can be given.
• Gap of 3-4 weeks: The dose may be reduced by one or two steps in the build-up schedule.
• Extended Gaps: The healthcare provider may need to restart the build-up phase from a much lower concentration to ensure safety.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level. This can lead to a systemic allergic reaction or anaphylaxis.

• Symptoms: Generalized hives, swelling of the throat, wheezing, low blood pressure, and rapid heart rate.
• Emergency Measures: Immediate administration of epinephrine (1:1000) via intramuscular injection, followed by antihistamines, corticosteroids, and supportive care (oxygen, IV fluids).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your doctor if you feel unwell on the day of your scheduled injection.

Most patients undergoing skin testing or immunotherapy with Botrytis Cinerea will experience some form of local reaction. These are generally not dangerous but indicate the body's immune response to the fungus.

• Local Redness (Erythema): The area around the injection site may turn red and feel warm to the touch. This usually appears within minutes and resolves within a few hours.
• Swelling (Wheal): A small, raised bump at the site of the injection or skin test. In immunotherapy, a local swelling smaller than the size of a half-dollar is considered a normal common reaction.
• Itching (Pruritus): Intense itching at the site of administration is very common and can be managed with topical cold compresses.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter. These may peak 6 to 12 hours after the injection and can be uncomfortable, sometimes causing a dull ache in the arm.
• Fatigue: Some patients report feeling unusually tired for several hours after their immunotherapy session.
• Headache: Mild tension-type headaches have been reported following the administration of fungal extracts.

• Systemic Hives (Urticaria): Itchy bumps appearing on parts of the body far from the injection site.
• Nasal Congestion and Sneezing: A temporary flare-up of hay fever symptoms shortly after the injection.
• Vasovagal Reaction: Fainting or lightheadedness due to the needle stick or anxiety, rather than an allergic reaction to the extract itself.

> Warning: Stop taking Botrytis Cinerea and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Difficulty Breathing: Wheezing, chest tightness, or a feeling that your airway is closing.
• Swelling of the Face or Throat: Angioedema involving the lips, tongue, or uvula.
• Rapid or Weak Pulse: Signs of cardiovascular collapse associated with anaphylactic shock.
• Severe Dizziness or Loss of Consciousness: A sudden drop in blood pressure (hypotension).
• Generalized Itching and Flushing: A 'feeling of impending doom' accompanied by widespread skin redness.

Botrytis Cinerea immunotherapy is generally intended for long-term use (3 to 5 years). Long-term side effects are rare but can include:

• Subcutaneous Nodules: Small, firm lumps under the skin at frequent injection sites. These are usually benign and resolve if the site is avoided for a period.
• Persistent Sensitization: In rare cases, a patient may become more sensitive to the extract over time, requiring a reduction in the maintenance dose.

While Botrytis Cinerea may not have a specific 'black box' in the same way as a high-risk oral medication, the FDA-approved class labeling for all allergenic extracts includes a prominent warning regarding Anaphylaxis.

Summary of Warning: This product can cause severe, life-threatening systemic reactions, including anaphylaxis. It must only be administered by healthcare providers experienced in the treatment of anaphylaxis. Patients with unstable or severe asthma are at a higher risk of fatal reactions. Patients must be observed for at least 30 minutes following administration. Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat reactions.

Report any unusual symptoms to your healthcare provider, even if they seem minor at the time.

Botrytis Cinerea extracts are potent biological agents. The most critical safety consideration is the risk of an IgE-mediated systemic allergic reaction. Because this extract is derived from a fungus, its protein composition can vary, and patients with high levels of sensitivity must be monitored with extreme vigilance. Patients should be in their baseline state of health before receiving an injection; if a patient is suffering from an acute respiratory infection or a flare-up of asthma, the injection should typically be postponed.

No specific individual black box warning exists for Botrytis Cinerea specifically, but it falls under the mandatory class warning for all Allergenic Extracts:

• Risk of Anaphylaxis: Severe reactions can occur even in patients who have previously tolerated the extract.
• Clinical Setting: Must be administered in a facility with emergency equipment (oxygen, epinephrine, IV fluids).
• Observation: A 30-minute post-injection wait is mandatory.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. The risk is higher during the build-up phase or when switching to a new vial of extract, as the new vial may be slightly more potent than the old one.
• Asthma Status: Patients with uncontrolled or severe asthma (FEV1 < 70% of predicted) are at a significantly higher risk for a fatal systemic reaction. Asthma must be stable before any injection is given.
• Cardiovascular Disease: Patients with pre-existing heart conditions may not tolerate the physiological stress of an allergic reaction or the effects of the epinephrine used to treat it.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) are at increased risk because these drugs block the effects of epinephrine, making anaphylaxis much harder to treat.

• Lung Function: For patients with asthma, a peak flow meter or spirometry may be used before the injection to ensure the patient is not in an active flare.
• Skin Assessment: The injection site must be checked before the patient leaves the office (at the 30-minute mark) and the patient should report any 'late-phase' reactions that occur 6-24 hours later.
• Vial Consistency: Clinicians must monitor the expiration date and lot numbers of the extracts to ensure potency consistency.

Botrytis Cinerea does not typically cause sedation or cognitive impairment. However, if a patient experiences a vasovagal reaction (fainting) or a systemic allergic reaction, they should not drive until they have fully recovered and been cleared by a physician.

There is no direct chemical interaction between alcohol and Botrytis Cinerea extracts. However, alcohol consumption can cause vasodilation and may theoretically increase the rate of absorption of the allergen or mask the early symptoms of an allergic reaction. It is generally advised to avoid heavy alcohol use on the day of an injection.

Immunotherapy is usually discontinued after 3 to 5 years of successful treatment. There is no 'withdrawal syndrome' associated with stopping Botrytis Cinerea, but the patient's allergy symptoms may gradually return if the desensitization process was not completed.

> Important: Discuss all your medical conditions, especially asthma and heart problems, with your healthcare provider before starting Botrytis Cinerea.

• Beta-Adrenergic Blockers (Beta-Blockers): While not an absolute contraindication in all guidelines, many clinicians consider the use of non-selective beta-blockers (like propranolol) a contraindication for immunotherapy. The clinical consequence is that if the patient has an anaphylactic reaction to Botrytis Cinerea, the beta-blocker will prevent epinephrine from working effectively, potentially leading to a fatal outcome.

• MAO Inhibitors (MAOIs): Drugs like phenelzine or selegiline can potentiate the effects of epinephrine. If a patient on an MAOI requires epinephrine for a reaction to Botrytis Cinerea, they may experience a dangerous spike in blood pressure (hypertensive crisis).
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs (like amitriptyline) can increase the cardiovascular sensitivity to epinephrine, increasing the risk of arrhythmias during emergency treatment.

• Antihistamines: Drugs like loratadine (Claritin), cetirizine (Zyrtec), or diphenhydramine (Benadryl) will suppress the skin's reaction to Botrytis Cinerea. This leads to false-negative results during diagnostic testing. Patients must typically stop antihistamines 3 to 7 days before skin testing.
• Systemic Corticosteroids: Long-term use of high-dose oral steroids may suppress the immune response, potentially making the immunotherapy less effective, though they do not usually interfere with the safety of the injection.

There are no known direct food interactions with Botrytis Cinerea extract. However, patients with 'Oral Allergy Syndrome' or cross-reactivity between molds and certain fermented foods (like aged cheeses or mushrooms) should discuss their diet with their allergist.

• St. John's Wort: May theoretically affect the metabolism of other medications used to treat allergic reactions, though no direct interaction with the fungal extract is documented.
• Licorice Root: May have mild corticosteroid-like effects that could theoretically interfere with skin testing results.

• Skin Prick Tests: As mentioned, antihistamines and certain antidepressants can interfere with the results.
• Serum IgE Tests: Botrytis Cinerea immunotherapy will eventually cause changes in the levels of specific IgE and IgG4 in the blood, which is an intended effect of the treatment rather than an interference.

For each major interaction, the management strategy usually involves either temporary discontinuation of the interacting drug (in the case of antihistamines before testing) or a careful risk-benefit analysis (in the case of beta-blockers).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any heart or blood pressure medications.

Botrytis Cinerea must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients whose asthma is not well-managed with standard medications are at a very high risk of a fatal bronchospasm if a systemic reaction occurs. The mechanism is the hyper-responsiveness of the airways to inflammatory mediators released during an allergic reaction.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The heart may not be able to handle the stress of an anaphylactic reaction or the high doses of epinephrine required to treat it.
• Known Hypersensitivity to Inactive Ingredients: Patients who have had a previous severe reaction to glycerin or phenol (used as preservatives in the extract) should not receive the product.

Conditions requiring careful risk-benefit analysis include:

• Autoimmune Diseases: There is a theoretical concern that stimulating the immune system with allergenic extracts could worsen conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis, though evidence for this is limited.
• Malignancy: Patients with active cancer may have altered immune systems that make immunotherapy less predictable.
• Severe Atopic Dermatitis: May make the interpretation of skin tests difficult due to skin irritability (dermatographism).

Patients allergic to Botrytis Cinerea may also show sensitivity to other fungi, such as Sclerotinia sclerotiorum or other members of the Sclerotiniaceae family. This is due to shared protein structures (homologous allergens) among different mold species. If you have had a severe reaction to other mold extracts, your doctor will use extra caution.

> Important: Your healthcare provider will evaluate your complete medical history and current respiratory health before prescribing Botrytis Cinerea.

Botrytis Cinerea is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm.

• General Consensus: Healthcare providers typically do not start a new course of immunotherapy during pregnancy because of the risk of anaphylaxis, which could cause fetal hypoxia (lack of oxygen).
• Maintenance: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment is often continued, as the risk of a reaction is lower once the maintenance phase is reached. Dose increases should be avoided during pregnancy.

It is not known whether the components of Botrytis Cinerea extract are excreted in human milk. However, because these are large protein molecules and the amount administered is very small, it is considered unlikely to pose a risk to the nursing infant. The decision to continue immunotherapy while breastfeeding should be made based on the mother's clinical need for the treatment.

As noted, Botrytis Cinerea is used in children for the diagnosis and treatment of mold allergies. However, the American Academy of Allergy, Asthma & Immunology (AAAAI) suggests caution in children under age 5 due to the difficulty of monitoring for systemic symptoms. In older children, immunotherapy has been shown to be effective and may even prevent the development of new sensitivities or the progression from rhinitis to asthma.

Clinical studies of Botrytis Cinerea did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. The primary concern in the elderly is the presence of comorbid conditions (like coronary artery disease or COPD) and the use of medications like beta-blockers, which increase the risk profile of immunotherapy.

There are no specific guidelines for the use of Botrytis Cinerea in patients with renal impairment. Because the product is a protein-based biological administered in minute quantities, it is not expected to accumulate in patients with reduced kidney function.

Liver function does not affect the clearance of allergenic extracts. No dosage adjustments are necessary for patients with hepatitis, cirrhosis, or other liver diseases.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you are pregnant or planning to become pregnant.

Botrytis Cinerea allergenic extract works by modulating the patient's immune response to the specific proteins found in the Botrytis fungus. The primary allergens in Botrytis (such as the 36-kDa protein) are recognized by B-cells, which produce IgE. Upon subsequent exposure, these IgE molecules trigger mast cells.

Immunotherapy with Botrytis Cinerea induces several changes:

1. 1IgG4 Induction: The body produces 'blocking' IgG4 antibodies that compete with IgE for the allergen, preventing mast cell activation.
2. 2T-Cell Shift: There is a shift from a Th2-dominated response (IL-4, IL-5) to a Th1-dominated response (IFN-gamma).
3. 3Regulatory T-Cells: Induction of IL-10 producing Tregs, which suppress the allergic inflammation.

The onset of action for diagnostic testing is rapid (15-20 minutes). For immunotherapy, the onset is slow; patients may not notice a reduction in symptoms for 6 to 12 months. The duration of effect can be long-lasting, often persisting for several years after the 3-5 year course of treatment is completed.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Intradermal) |

| Protein Binding | N/A (Degraded by proteases) |

| Half-life | Days (immunological effect lasts years) |

| Tmax | 30-60 minutes (systemic absorption) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (as peptide fragments) |

Botrytis Cinerea extract is a sterile liquid containing the water-soluble antigens of the fungus. It is typically preserved with 0.45% phenol and may contain 50% glycerin for stability. The molecular weight of the constituent allergens ranges from 10,000 to over 70,000 Daltons. It is soluble in aqueous buffers.

Botrytis Cinerea is classified as a Non-Standardized Fungal Allergenic Extract. It is part of the broader category of 'Allergenics,' which includes extracts for pollens, animal dander, and insects.